← All trials
NCT05039359
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 26, 2022
- Primary completion
- May 22, 2023
- Completion date
- May 22, 2023
- First posted
- Sep 9, 2021
- Last posted
- Oct 30, 2023
- Enrollment
- 54
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- InCarda TherapeuticsLead sponsor
- InCarda TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.